
Canada has granted interim authorization to Eli Lilly's antibody drug for treating COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions, the drug-maker said on Friday.
from CBC | Health News https://ift.tt/2UReFRa
Aucun commentaire:
Enregistrer un commentaire